Morepen Laboratories reports 20% profit decline for FY26
Consolidated net profit dropped to ₹94.88 crore as revenue remained flat. The company also pushed the effective date for its medical devices business transfer to April 1, 2026.
— 4 earlier stories on Morepen Laboratories Ltd. →What's new
- Consolidated net profit fell 19.6% year-on-year to ₹94.88 cr.
- Revenue for the year remained flat.
- The appointed date for the medical devices business transfer is now April 1, 2026.
Why this matters
The results confirm a trend of margin pressure already known to the market. The business transfer delay is a procedural adjustment rather than a change in strategy.
What we're watching
- Any recovery in margins in the upcoming quarterly results.
- Progress on the medical devices business transfer after the new April 1 date.
- Dividend payout consistency.
The full read
Morepen Laboratories closed FY26 with a consolidated net profit of ₹94.88 crore, marking a 19.6% decline from the ₹118.02 crore reported in the prior year. Revenue remained flat throughout the period. The board also confirmed a revision to the business transfer agreement for its medical devices unit, pushing the appointed date to April 1, 2026. These figures and the transfer timeline align with information already shared with the market. Other board actions, including the recommendation of a ₹0.20 per share dividend and the re-appointment of cost auditors, are routine. The filing contains no new price-sensitive information.
Questions answered
- How did Morepen Laboratories perform in FY26?
- The company reported a consolidated net profit of ₹94.88 crore, a 19.6% decline from the ₹118.02 crore recorded in the previous year. Revenue remained flat over the same period.
- What is the status of the medical devices business transfer?
- The company has revised the appointed date for the business transfer agreement to April 1, 2026. This is a procedural update to a previously announced transaction.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹0.20 per share.
- Are there any new price-sensitive developments in this filing?
- No. The financial results and the business transfer update were already disclosed to the market in prior filings.
Story so far
All notes on MOREPENLAB →- 26 May 2026 · 5:58 PM IST Morepen Laboratories reports 20% profit decline for FY26
- today Morepen Laboratories profit jumps 69% as CDMO production kicks off
- 1d ago Morepen Laboratories profit drops 20% as margins tighten
- 1d ago Morepen Laboratories profit drops 20% on flat revenue
- 7d ago Morepen locks in medical devices chief with subsidiary shares